Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade.

ABSTRACT: Sequential combination of immunogenic cell death (ICD)-induced interventions with subsequent immunotherapy has shown efficacy in preclinical models and clinical evaluation. Recently, a clinical trial enrolling small cell lung cancer patients treated with amrubicin together with PD-1 blockade confirmed the notion that ICD sensitizes tumors to immune checkpoint inhibitors.

SUBMITTER: Kroemer G 

PROVIDER: S-EPMC8565809 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature